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Abstract
Background: Nutrition management of pediatric intestinal failure (IF) requires interdisciplinary coordination of parenteral
nutrition (PN) and enteral nutrition (EN) support. Nutrition strategies used by specialists in pediatric intestinal rehabilitation
to promote gut adaptation and manage complications have not been previously summarized. Methods: A practice survey was
distributed to members of the dietitian subgroup of the American Society for Parenteral and Enteral Nutrition Pediatric Intestinal
Failure Section. The survey included 24 open-ended questions related to PN and enteral feeding strategies, nutrition management
of PN-associated liver disease, and laboratory monitoring. Results:Dietitians from 14 centers completed the survey. Management
components for patients at risk for cholestasis were consistent and included fat minimization, trace element modification, avoiding
PN overfeeding, and providing EN. Parenteral amino acid solutions designed for infants/young children are used in patients <1 or
2 years of age. Trace minerals are dosed individually in 10 of 14 centers. Eleven centers prescribe a continuous infusion of breast
milk or elemental formula 1–2 weeks after resection while 3 centers determine the formula type by the extent of resection. Most
(86%) centers do not have a protocol for initiating oral/motor therapy. Laboratory panel composition varied widely by center. The
selection and frequency of use depended on clinical variables, including cholestatic status, exclusive vs partial PN dependence,
postrepletion verification vs routine monitoring, intestinal anatomy, and acuity of care. Conclusion: EN and PN management
strategies are relatively consistent among U.S. centers. Collaborative initiatives are necessary to define better practices and establish
laboratory monitoring guidelines. (Nutr Clin Pract. 2018;33:528–538)
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Short bowel syndrome (SBS) may occur after massive
resection of the small bowel due to necrotizing enterocolitis
or conditions such as small bowel atresia, malrotation
with midgut volvulus, or gastroschisis and is the most
common cause of intestinal failure (IF) in children.1 IF
can also occur due to impaired intestinal absorption or
altered motility in children with microvillus atrophy or
intestinal pseudo-obstruction. Pediatric IF is a clinical
condition characterized by malabsorption, malnutrition,
and growth retardation.2-4 Management of children with
IF is complex but can be optimized by interdisciplinary
coordination of nutrition support, medical therapies, and
surgical interventions.5 Many children with IF experience
progressive adaptation of their remaining small bowel over
a few months to years with eventual independence from
parenteral nutrition (PN). However, hepatobiliary disease
is a chronic complication of long-term use of PN and is
a major contributor to the high morbidity and mortality
of children with IF.5,6 Nutrition management during the
period of intestinal adaptation includes maintenance of
fluid and electrolyte balance as well as enteral nutrition
(EN) and PN support.7 Pediatric nutrition specialists rely on
established nutrition guidelines and interventions intended
to promote adaptation of the remnant small bowel and facil-
itate weaning of PN and achievement of enteral autonomy
before complications occur.8
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Nutrition practice guidelines for the general manage-
ment of children receiving PN have existed for several
decades.9-11 In 2004, a 2-part review of intestinal reha-
bilitation (IR) and SBS management by DiBaise et al1
was published. Part I included an overview of the patho-
physiology of SBS and a discussion of luminal nutrients,
hormones, growth factors, and other substances that may
enhance adaptation. Part II provided nutritionmanagement
guidelines for SBS with dietary guidelines by the presence or
absence of a colon, suggestions for micronutrient supple-
mentation, and a discussion of the clinical benefits of man-
agement by an interdisciplinary IR team.5 More recently,
detailed macronutrient and micronutrient recommenda-
tions for the management of children with IF have been
published. These reports include initial postoperative as well
as short-term and long-term PN and EN recommendations
and laboratory monitoring guidelines12,13 with an emphasis
on the prevention of nutrient deficiencies and complica-
tions, such as IF-associated liver disease (IFALD).14 In
addition, multiple cohort studies have reported benefits of
restricting intravenous (IV) soy-based fats as ameans of pre-
venting IFALD,15 as a treatment for infants diagnosed with
IFALD,16 and after reversal of cholestasis using fish oil–
based IV emulsion.17 Although clinical nutrition guidelines
for the management of children with IF are available, most
research that has been conducted in this population has been
descriptive or semi-experimental in design. Clinical trials are
costly and often require multicenter collaboration to obtain
an adequate sample size. However, experimental studies
to establish evidence-based criteria for care are needed.12
No published review of current nutrition practice for this
population has been reported. The purpose of this study is
to (1) summarize the nutrition strategies used by physicians
and dietitians in pediatric IR to promote gut adaptation and
manage complications in children with IF and (2) compare
current nutrition practice with existing recommendations.
Methods
The Pediatric Intestinal Failure Section of the American
Society for Parenteral and Enteral Nutrition (ASPEN) was
initiated in 2014. The section includes physician, dietitian,
and pharmacy subgroups. The dietitian subgroup includes
members from 27 pediatric hospitals within the United
States and 4 international facilities. The short-term goals of
the dietitian subgroup are (1) to prepare nutrition education
materials for use by healthcare professionals and care-
giver(s) of children with IF and (2) to create a network of
practitioners with a specialty in pediatric IF for the purpose
of sharing resources and discussing nutrition practice issues.
A long-term goal of the subgroup is to develop nutrition
research questions and form multicenter research collabo-
rations. A qualitative nutrition practice survey developed by
the dietitian subgroup was electronically distributed to all
subgroup members between January and September 2015.
The survey included 23 primarily open-ended questions
related to IR center composition, PN and enteral feeding
strategies, nutritionmanagement of IFALD, and laboratory
monitoring (Table 1). The study was determined to be




Dietitians from 14 centers completed the survey. The cen-
ters were located in Atlanta, Georgia; Aurora, Colorado;
Baltimore, Maryland; Boston, Massachusetts; Cleveland,
Ohio; Cincinnati, Ohio; Columbus, Ohio; Grand Rapids,
Michigan; Indianapolis, Indiana; Little Rock, Arkansas;
New Haven, Connecticut; St Louis, Missouri; and Seattle,
Washington. Seven of the 14 centers (50%) have an or-
ganized interdisciplinary IR service that manages children
with IF upon discharge from the neonatal intensive care
unit (NICU). While in the NICU, children with IF are
managed by the NICU service with consultation from the
IR team. Centers without an organized IR team use both
the gastroenterology and pediatric surgery services for care
management.
PNManagement
Parenteral amino acid solutions designed for infants and
young children are used in patients <1 year of age in all
but 1 center, which uses the product up to 2 years of age. A
standard parenteral amino acid solution is used thereafter.
Twelve of 14 centers (86%) include protein calories when
calculating total caloric intake. While excluding protein
calories when calculating total caloric intake has not
been a standard of care for many years, we assessed
whether dietitians working in IR centers still follow this
practice. The general practice of dosing trace elements and
cycling/tapering of PN solutions is shown in Table 2. Eleven
of the 14 centers (79%) reported monitoring serum levels
of trace elements as a result of reduced intake, specifically
copper, selenium, and zinc. Dietitians from 10 centers
reported that the decision to initiate iron supplementation
is dependent upon laboratory determination of deficiency.
The general consensus was that enteral iron should be
provided when there is a sufficient length of proximal small
bowel and tolerance to enteral feedings is established. IV
iron is selected in the case of an extremely short bowel
and feeding intolerance where PN is the primary source of
nutrition. PN support standards of care did not significantly
differ for children who receive long-term PN (>1 month)
at the centers surveyed. However, 4 center dietitians (29%)
noted that laboratory monitoring differed by the length
of time on PN with the inclusion of parameters for
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Table 1. Pediatric Intestinal Failure Nutrition Practice Survey Questions.
Number Question
1 What medical services/teams manage your patients with IF?
2 What is your standard protein source for PN?
3 Do you use the same protein source for all patients (yes/no)?
4 If you use the same protein source for all patients, under what circumstances would you use a specialized
parenteral amino acid solution?
5 Do you use a trace mineral package or dose minerals individually for patients on PN?
6 For patients with IF on PN, when would you provide supplemental iron?
7 If supplemental iron is provided, how is it given and under what circumstances would each method be chosen?
8 Do you have any protocols for patients receiving long-term (>1 month) PN without EN intake?
9 Do you include protein calories when calculating the caloric intake of patients on PN?
10 What is your practice regarding cycling PN?
11 What is your practice regarding tapering of PN?
12 If you are caring for a patient with IF who is at risk for cholestasis, what is your general philosophy for
nutrition management?
13 If you are caring for a patient with IF who has cholestasis, what is your standard practice for nutrition
management?
14 If you are caring for a patient with cholestasis, what is your institution policy with regard to the provision of
parenteral trace minerals?
15 How many days are your patients with IF typically ordered “nothing by mouth” status post resection?
16 What is your formula of choice for children with IF status postresection?
17 What is your typical mode of feeding after resection?
18 What oral supplements do you typically recommend for patients with IF?
19 Do you have a protocol for starting oral/motor therapy for oral feedings after resection?
20 How soon are oral feedings initiated in children with IF at your center?
21 Do you use urine sodium to determine whether a patient with IF requires sodium supplementation?
22 What laboratory tests do you routinely follow in patients with IF on PN? Include macronutrients and
micronutrients and interval for follow-up (eg, daily, weekly, monthly).
23 Which of the following parameters do you follow in patients receiving PN?




e. Nonprotein nitrogen/calorie ratio
f. Other:
EN, enteral nutrition; IF, intestinal failure; PN, parenteral nutrition.
trace elements and essential fatty acid deficiency to the
monitoring schedule for those on long-term PN.
Enteral/Oral Management
Eight of the center dietitians (57%) reported a length of
time that children with IF are typically unable to receive
enteral/oral feeding after initial surgery (range, 5 days to 2
weeks). The type of EN and oral supplementation provided
to children with SBS after resection varied between centers
(Table 3).Most centers (n= 13) prefer the administration of
continuous feeds via nasogastric tube (NG) or gastrostomy
tube (GT) postresection, with 2 also recommending small
oral feedings as tolerated. One center prefers to provide
oral feeding in the absence of feeding intolerance and if
the child is developmentally ready for oral intake. Vitamin,
trace element, and fiber supplements are the products most
commonly prescribed.
Most centers (n = 12) do not have a formal protocol
for the initiation of oral feedings after small bowel resec-
tion. Nine of these centers do consult with occupational
or speech therapy for the purpose of encouraging age-
appropriate complementary food intake when the child is
developmentally ready. Two centers reported that they use a
protocol for starting oral intake. Of these, 1 center begins
with nonnutritive oral feedings of human milk or infant
formula and advances to small-volume oral boluses when
trophic feedings are tolerated. This center also initiates solid
foods at 6 months of age beginning with vegetables followed
by bananas, grains, meats, and fruit. The second center
begins with 2 oral feedings per day under the supervision of
an occupational or speech therapist when enteral feedings
have reached 3 mL/h. The timing of initiation of oral feed-
ings varies by center. Most centers did not report an exact
time point for the initiation of feedings but all provided
qualifications for initiation of oral feedings (Table 3).
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Table 2. Practice Responses to Questions Related to Parenteral Nutrition Management.
Survey Question Response Rate Practice Response
Number of Centers
per Response
Do you use a trace element
package or dose minerals
individually for patients on
PN?
14 of 14  Trace element package only
 Individual dosing





What is your practice regarding
cycling of PN?
11 of 14 Cycling criteriaa
 Medical stability
 Minimum 3 months corrected age
 Weight >5 kg
 Intake of >50 kcal/kg/d from EN






14 of 14 Cycling strategy
 1- to 2-hour increments
 2- to 4-hour increments
 No more than 4 hours off PN (infants)





What is your practice regarding
tapering of PN?
14 of 14 Tapering strategy
 minutes up and down
 30 minutes up and 1 hour down
 1 hour up and down
 2 hours down only
 hours up and down







EN, enteral nutrition; PN, parenteral nutrition.
aCenters may have reported >1 response.
Prevention and Management of IFALD
The center dietitians were queried regarding general
philosophies toward the nutrition management of patients
at risk for IFALD. Limiting IV fat was a major component
of the nutrition management of children with IF at risk
for developing cholestasis at all centers (Table 4). Among
the centers employing some form of fat restriction, typical
dosing was limited to 1–2 g/kg/d. The second major theme
among the centers participating in the survey was providing
EN in the form of trophic feedings or aggressive advance-
ment of feedings. Monitoring parameters included glucose
infusion rate (GIR), triene/tetraene ratio, trace elements,
and weight gain and linear growth. The center dietitians
were also asked to describe their standard practice for the
nutrition care of a child with IF as well as IFALD. Fat
minimization or restriction is the most common element of
nutrition support practice among all centers included in the
survey (Table 4). Each center typically limits IV fat to 1
g/kg/d in patients with cholestasis. However, some centers
(n = 3) reduce fat dose to <1 g/kg/d either by providing
a restricted daily dose or providing 1 g/kg 2 or 3 days
per week. Four dietitians reported that trace elements were
dosed individually at their centers for children with IFALD.
Two centers provide a reduced amount of copper and 3
centers remove manganese entirely from the PN solution.
Laboratory/Biochemical Monitoring
An overview of the IF center dietitian practice survey
responses to questions related to laboratory/biochemical
monitoring in children with IF is shown in Table 5. Most
centers (93%) use urine sodium to determine whether a
patient requires sodium supplementation. Dietitians from
all centers listed a variety of panels, vitamins, trace ele-
ments, and miscellaneous laboratories whose selection and
frequency of use appeared to depend largely on a patient’s
clinical variables such as noncholestatic vs cholestatic status,
exclusive vs partial PN dependence, postrepletion verifica-
tion vs routine monitoring, intestinal anatomy, and acuity
of care (ie, NICU vs general floor vs outpatient). Dietitians
from all centers use the GIR (mg/kg/min) as a clinical
parameter for patients receiving PN.
Discussion
While the provision of PN has resulted in a reduced
mortality rate for infants and children with IF, serious and
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What is your formula of choice
for children with intestinal
failure status postresection?
14 of 14  Human milk or elemental infant formula
 Amino acid–based infant formula








14 of 14  Vitamin and trace element supplements










How soon are oral feedings
initiated in children with
intestinal failure at your
center?
14 of 14  As soon as possible
 Depends on stool/ostomy output
 Varies individually
 Within 7–10 days
 Medically stable for 2 weeks on EN
 Age appropriate (>37 weeks)
 Developmentally appropriate; 2–3 days after EN initiated
 After EN is initiated











aHuman milk or an elemental infant formula with significant resection; polymeric infant formula with minimal resection.
bCenters may have reported >1 response.
potentially life-threatening complications may still occur as
a result of long-term use of PN. Growth failure continues
to be observed in a high percentage of children with IF,18
the risk of nutrient deficiencies has been shown to increase
during the transition from PN to EN,19-21 and multiple
years of PN therapy can result in the development of
IFALD.14 The nutrition care of children with IF should
be individualized based upon the intestinal anatomy and
medical condition of each patient. The EN and PN man-
agement strategies reported by the pediatric IF practitioners
who participated in this survey are relatively consistent.
Only half of the dietitians surveyed function as part of an
organized IR program. The strategies currently being used
are designed to support intestinal adaptation and reverse
or slow the progression of complications. However, clinical
and laboratory monitoring practices vary considerably be-
tween centers. Collaborative initiatives such as the Pediatric
Intestinal Failure Section of ASPEN are ideally suited to
define better practices and establish monitoring guidelines
through multicenter research efforts.
PN is an established treatment for children with IF
that must be carefully managed to prevent or delay the
development of PN-associated complications.22 Methods
currently recommended for the prevention of IFALD in-
clude avoiding overfeeding, providing a balanced distri-
bution of macronutrients in the PN solution, cycling the
PN infusion, and providing EN as tolerated.23 All of the
dietitians surveyed reported that cycling of the PN solution
is a treatment goal in their practices and that advancement
(reduction in PN infusion hours) is determined by blood
glucose tolerance. Providing a dextrose solution over fewer
hours may result in a GIR greater than what is currently
recommended for children without cholestasis (<12–14
mg/kg/min).23 Therefore, monitoring for hyperglycemia or
hypoglycemia is essential during the cycled infusion and
while the infusion is off. Abrupt cessation of PN has been
reported to be well tolerated in children >2 years of age.24
However, many children with IF are <1 year of age at the
time of diagnosis.25 Tapering of the dextrose solution over
30–60 minutes before discontinuation may prevent rebound
hypoglycemia and is a common practice reported by the
dietitians who completed our survey.
Most centers provide human milk or amino acid–based
infant formula as the primary source of nutrition for chil-
dren with SBS. This practice aligns with recommendations
from the current literature. In a retrospective medical record
review of 30 neonates with SBS, Andorsky et al26 reported
that the use of either human milk or an amino acid–based
formula was associated with a shorter duration of PN.
Human milk contains long-chain fatty acids, free amino
acids such as glutamine, and growth factors that paired
with immune-enhancing properties may assist in intestinal
adaptation. An amino acid–based formula may decrease
the duration of PN since it contains a high percentage of
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Table 4. Practice Responses to Questions Related to Prevention and Management of Intestinal Failure–Associated Liver Disease.
Survey Question Response Rate Practice Response
Number of Centers
per Response
If you are caring for a patient
with short bowel syndrome
who is at risk for cholestasis,
what is your general
philosophy for nutrition
management?a




 Dose trace elements individually
 Wean PN
 Monitor serum levels of trace elements










If you are caring for a patient
with short bowel syndrome
who has cholestasis, what is
your standard practice for
nutrition management?
14 of 14  IV fat restriction
 Initiate/advance enteral nutrition
 Cycle PN
 Dose trace elements individually
 Provide fish oil–based IV fat emulsion
 Monitor serum levels of trace elements
 Avoid overfeeding
 Monitor for essential fatty acid deficiency
(triene/tetraene ratio)
 Limit parenteral protein dose
 Do not exceed maximum recommended glu-
cose infusion rate













EN, enteral nutrition; IV, intravenous; MCT, medium-chain triglyceride; PN, parenteral nutrition.
aCenters may have reported >1 response.
long-chain fatty acids, which may promote mucosal
adaptation.27 Although long-chain fatty acids promote
adaptation and provide a source of essential fatty acids,
medium-chain triglycerides are advantageous because they
can be directly absorbed by enterocytes. Most amino
acid–based formulas contain a mixture of long-chain and
medium-chain triglycerides, which may explain why most
centers prefer these formulas if human milk is not available.
Some researchers argue that there is insufficient evidence to
support 1 type of formula over another for patients with
SBS. Ksiazyk et al28 conducted a prospective, randomized,
crossover, double-blind study of 10 children receiving infant
formula containing either hydrolyzed or intact protein.
Children were trialed on each formula for 30 days (crossover
on day 31), and nitrogen balance and lactulose/mannitol
excretion ratio (to measure intestinal permeability) were
evaluated on days 1, 31, and 61 of the study. The researchers
reported that the 2 types of formula did not yield a sig-
nificant difference in intestinal permeability, caloric/energy
intake, weight gain, or nitrogen balance. However, feeding
tolerance was not assessed, and all infants were receiving
30% of calorie intake from hydrolyzed enteral feeds before
beginning the study protocol. In a review of published data
relevant to feeding strategies in children with SBS, Olieman
et al29 recommended the use of human milk or standard
polymeric formula depending on the age of the child.
Most centers initiate continuous feedings postresection
since they are believed to be better tolerated than bolus
feeds and promote adaptation via continual saturation of
the intestinal lumen. However, limited research evidence
exists on the topic. A frequently cited study to support the
use of continuous feeds was conducted by Parker et al30
over 30 years ago. The researchers reported that continuous
feedings yielded a significant increase in body weight and
enteral balance (enteral retention of formula and nutrients)
compared with oral bolus feeds. Unfortunately, the sample
size was very small (n = 9), and only 2 of the infants had
SBS. A more recent randomized crossover study of nutrient
absorption by mode of nutrition therapy (tube feeding
alone, oral feeding alone, combination of tube and oral
feeding) was conducted in adults with SBS (n = 15). Results
revealed significantly greater absorption of protein, fats, and
energywhen a tube feeding was used alone or in conjunction
with oral feeding compared with when oral feeding was used
alone.31 Although continuous feedings may be better tol-
erated and improve nutrient absorption, bolus feedings are
desirable as they mimic the typical infant eating pattern and
are therefore more physiological. Bolus feedings allow for
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Table 5. Practice Responses to Questions Related to Laboratory/Biochemical Monitoring.
Survey Question Response Rate Practice Response
Number of Centers
per Response
Do you use urine sodium to determine
whether a patient with short bowel
syndrome requires sodium
supplementation?
14 of 14  Yes
 Yes, occasionally






What laboratory tests do you routinely
follow in patients on PN with short
bowel syndrome or intestinal failure?
Include macronutrients and
micronutrients and interval for
follow-up (eg, daily, weekly,
monthly).a
13 of 14b Panels (daily to monthly): CBC, CMP,
BMP
Vitamins (every 3–12 months): serum
retinol, retinol binding protein, RBC
folate, vitamin B-12, methylmalonic
acid, vitamin D, vitamin E
Trace elements (every 3–12 months):
serum copper, serum zinc, selenium
(RBC and serum), serum iron, total
iron binding capacity, ferritin
Other (every 3–12 months): magnesium,
phosphorous, serum triglycerides, C-
reactive protein, prothrombin time, in-
ternational normalized ratio, thyroid-




Which of the following parameters do
you monitor in patients receiving
PN?a




E. Nonprotein calorie/nitrogen ratio










BMP, basic metabolic panel; CBC, complete blood count; CMP, comprehensive metabolic panel; PN, parenteral nutrition; RBC, red blood cell.
aCenters may have reported >1 response.
bQuestion was not answered by 1 center.
periods of fasting, which may prevent hyperinsulinemia32
and promote appropriate bacterial clearance.33
Vitamins and trace elements were the supplements most
often reported to be prescribed. Several dietitians also
reported use of a carbohydrate and fat modular product,
purees, and pectin/fiber. Vegetable oils such as canola,
safflower, or flaxseed can be added to tube feedings to
increase caloric intake or supplement essential fatty acids
without adding significant volume. Fiber is often added to
feedings to slow bowel transit time and reduce stool output,
which assists with nutrient absorption and subsequently
growth.34 Soluble fiber is beneficial because it is fermented
into short-chain fatty acids, which can be metabolized by
colonocytes for energy.35 In a 2010 practice paper published
in the Journal of the Academy of Nutrition and Dietetics,
the authors noted that dietary fiber should be used when
developmentally appropriate (age 4–6 months) in the pres-
ence of a colon.29 Pectin, a water soluble dietary fiber,
may slow the motility of gastric contents and increase the
contact of nutrients with the intestinal lumen. However,
the dose used (1%–3% solution) is based on a single case
series of 2 formerly premature infants who had small bowel
resections.36 Drenckpohl et al37 documented the benefits of
using stage 2 baby food green beans to infant feedings in a
case series. After the addition of green beans to formula (4-
oz jar of green beans per 8-oz formula), stool consistency
improved in all of the infants. The researchers concluded
that the mixture of 32% soluble and 68% insoluble dietary
fiber present in the green beans (2–3 g fiber per 4-oz jar)
assisted in improving stool consistency.
While most dietitians did not report using a protocol for
initiating oral/motor therapy, most centers do recommend
therapy when appropriate. Oral aversion is common in
patients who receive nutrition support for a prolonged
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period of time. Consequently, oral motor therapy and early
oral feedings are important to the rehabilitation process.
These therapies may also provide beneficial support for
families who become frustrated with lack of progress with
oral feeds.38 Although most centers did not report an exact
time for initiation of complementary oral feedings, some
use criteria to assess readiness or generally stated that they
would begin oral feeds as soon as possible. The initiation
of oral feeds as soon as developmentally and medically
appropriate is important to prevent oral aversion.38 The
first year of life is the most critical period for the de-
velopment of oral feeding skills.33 Oral feeding promotes
epidermal growth factor release from salivary glands and
increases gastrointestinal secretion of trophic factors.33
Small bolus feedings by mouth (equal to or less than the
volume tolerated continuously per hour) should be trialed
to encourage development of swallowing. Solid food should
be introduced at a developmentally appropriate age under
the guidance of a feeding therapist.12 Unfortunately, no
clinical studies have been conducted to identify the preferred
time of initiation of complementary solid foods or the
optimal oral diet for children with SBS.29 Current nutrition
recommendations are subdivided by colon status. A high-
carbohydrate (50%–60% of energy), lower fat (20%–30%
of energy) diet may be indicated for patients with a colon
while a higher fat (30%–40% of energy), lower carbohydrate
(40%–50% of energy) diet may be preferred when the colon
is absent.5 Complex carbohydrates may be better tolerated
than simple sugars, and patients with a colon may need to
avoid or restrict oxalate intake to decrease the risk of oxalate
renal stones.5
Several components of nutrition management for chil-
dren at risk for IFALD were consistent among all centers
and were similar if not the same as those principles used
for patients at risk for developing cholestasis. The literature
related to minimization of soy-based fat emulsion (1
g/kg/d) is primarily observational. Although restriction of
IV fat emulsion has been shown to reduce total bilirubin
levels in children with IFALD,16 the effect of the accom-
panying caloric reduction on growth in the IF population
is unknown.14 Levit et al39 conducted a clinical trial that
examined the safety and efficacy in preventing IFALDusing
a low-dose soy-based fat emulsion (1 g/kg/d) vs a control
dose (3 g/kg/d) in preterm infants (n = 136) after 14
days of PN. The authors reported that after 28 days of
life, no difference in growth or reduction of cholestasis
was observed between the randomized groups. However,
this was not a surgical population requiring prolonged PN
support, and the determination of cholestasis (15% of the
total bilirubin at 28 days of life) differed from the definition
used in other fat minimization studies (conjugated bilirubin
>2 mg/dL).15,16 Essential fatty acid deficiency was observed
in infants with IFALD who were placed on a soy-based fat
emulsion reduction protocol (1 g/kg/d twice weekly) for a
mean of 50 days (range, 11–712 days).16 Deficiencies were
mild and resolved within 1–2 months after the number of
days of fat infusion were increased. The authors noted
the importance of monitoring markers of essential fatty
acid deficiency during fat minimization and suggested that
absolute values of linoleic and α-linolenic acid be examined
vs the triene/tetraene ratio, which is frequently used.16 Given
the importance of dietary fat on infant brain development,
there is concern about the effect of fat minimization on
the long-term neurodevelopment of infants with IFALD
treated with low-dose IV fat. Few studies have assessed this
risk. However, preliminary findings at 1 institution showed
that infants treated with IV fat emulsion reduction had
mostly normal neurodevelopmental outcomes at ages rang-
ing from 2–5 years.40 Another institution recently published
data showing no adverse effect of low-dose IV soy-based
fat emulsion on neurodevelopment or growth at 2 years of
age in a cohort of 15 premature infants compared with 15
premature infants who received standard dosing.41
The use of ω-3 or fish oil–based fat emulsions is associ-
ated with resolution of biochemical markers of IFALD42-44
but lacks rigorous clinical studies in the pediatric IF pop-
ulation. Puder et al45 conducted a trial of fish oil–based
fat emulsion in 42 infants with SBS and cholestasis. Of
the 38 patients who survived or were not transplanted, 19
(50%) experienced reversal of cholestasis (direct bilirubin
2 mg/dL). The fish oil–based fat emulsions are thought
to improve liver function due to the anti-inflammatory
properties of the ω-3 fatty acids and improved triglyceride
clearance.42 In addition, they lack the phytosterols of soy-
based fats, which are thought to be relatively hepatotoxic.42
However, there are reports of continued liver disease de-
spite resolution of cholestasis,46-48 and similar reductions
in cholestasis are achieved by restricting traditional soy-
based IV fats. Fish oil–based fat emulsions are not cur-
rently approved by the Food and Drug Administration
(FDA) for use in the United States but remain available
for use under research or compassionate use protocols.
Alternatively, Smoflipid (Fresenius Kabi, Bad Homburg,
Germany), an IV fat emulsion that contains soybean oil,
medium-chain triglycerides, olive oil, and fish oil, is FDA
approved for use in adults. Although the safety and efficacy
of using Smoflipid in pediatric patients have not yet been
established,49 randomized controlled trials have examined
Smoflipid vs soy-based fat emulsion with encouraging re-
sults, including decreased serum γ -glutamyl transferase50
and total bilirubin51 in the Smoflipid groups. In a small
retrospective review, conjugated bilirubin decreased within
2 weeks after a change to Smoflipid from a soy-based fat
emulsion in children with IFALD.52
Reducing or removing trace elements from PN solutions
is a proposed strategy to decrease the risk of IFALD.13 Since
copper is eliminated via biliary excretion, parenteral intake
of copper may need to be reduced when IFALD is present,
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while increased provision of copper may be necessary in
patients with a jejunostomy or other biliary output.10,53 Of
note, copper deficiency has been reported with copper-free
PN.53 Recent studies examining the practice of reducing
or removing copper from PN solutions of cholestatic pa-
tients have shown that a standard intake of 20 mcg/kg/d
for infants may be safe, and it is suggested that copper
levels be assessed prior to reducing or removing copper
from PN solutions.54-56 Manganese supplementation may
not be necessary for children with IFALD as manganese
is a contaminant in PN solutions.38 Therefore, use of
individual trace element preparations vs a packaged trace
element preparation may be the best practice in patients
with IFALD.10,38 Carefulmonitoring of trace element status
when micronutrients are removed from PN is warranted.
Provision of EN in some form continues to be a sig-
nificant component of the nutrition support practice for
patients with IFALD. Expert opinion based on experience
and available research seems to focus on advancing enteral
feedings to promote intestinal adaptation and weaning PN
support while maintaining proportional growth. EN is be-
lieved to promote intestinal adaptation by stimulating mu-
cosal hyperplasia, gastrointestinal hormone secretion, and
pancreaticobiliary secretions.1 These mechanisms may also
protect against the development of IFALD by improving
biliary flow and decreasing the risk of bacterial overgrowth,
which may further inhibit bile secretions.23 Most experts
agree on starting EN as early as medically feasible and
advancing slowly while taking advantage of available strate-
gies as previously discussed, including continuous feeds,
refeeding of ostomy output into distal mucous fistula, and
fiber supplementation.13,22,38
Our survey revealed considerable variability in labo-
ratory test selection and monitoring frequency among
pediatric IF practitioners. Most dietitians responding to
the survey indicated the use of specific laboratory panels
at defined intervals to address the reported high preva-
lence of micronutrient deficiencies in patients with pedi-
atric IF.4,19,21,57 The laboratory monitoring practices of
most centers are generally reflective of the evidence-based
literature. Most centers routinely monitor urine sodium
due to the known association of growth failure with a
low urine sodium level, particularly in those patients with
jejunostomies, ileostomies, and colostomies.58 Many centers
have laboratory monitoring protocols, similar to published
recommendations from children’s hospitals with established
IR centers, to address the high risk of micronutrient de-
ficiency in their patient populations.12,57 Although infre-
quently mentioned by survey respondents, the monitoring
of iodine status in pediatric IF patients has garnered much
attention in the literature since the submission of survey
results, particularly in light of numerous studies demon-
strating the potential increased risk of iodine deficiency in
pediatric patients requiring long-term PN supplementation.
Two case studies and 1 retrospective cohort analysis re-
vealed varied use of iodine biomarkers (thyroid-stimulating
hormone, T4, serum vs urine iodine) and varied frequency
of monitoring59-61 in investigating iodine deficiency in their
chronic PNpediatric patients. The high variability in labora-
tory test selection and monitoring frequency may be reflec-
tive of a lack of national guidelines. Our survey has revealed
the importance of continual collaboration among centers to
establish biochemical monitoring standards, particularly in
the absence of the large numbers of subjects needed for well-
executed clinical trials in this subspecialty area of practice.
Areas in which collaboration may be beneficial include the
following:
 Designating the relevant micronutrients for monitor-
ing and the most reliable indicators (eg, erythrocyte
vs plasma, serum vitamin B-12 or serum methyl-
malonic acid or both)
 Establishing the monitoring frequency and indi-
cations for any protocol variance (eg, intestinal
anatomy, liver function, PN dependent vs nondepen-
dent)
 Facilitating monitoring across the inpatient/home
health spectrum of care, particularly in regard to
the management of parenteral trace element product
shortages62
The design of the practice survey has the advantage of
permitting collection of data that might not be captured in
a closed-ended questionnaire. However, this type of study
survey also has several limitations. Questions are subject
to individual interpretation (eg, what supplements do you
typically recommend for patients with IF?), and specific
components may not have been reported due to the open-
ended format (eg, what laboratory tests do you routinely
follow in patients with IF on PN?).
Conclusion
EN and PN management strategies in the presence and
absence of cholestasis are relatively consistent among U.S.
practitioners caring for children with IF. However, labora-
tory monitoring practices vary widely among centers. Al-
though only half of the dietitians surveyed function as part
of an organized IR program, interdisciplinary management
and early referral of children dependent on PN to an IRpro-
gram can result in positive outcomes, including cessation of
PN support, accelerated growth, and improved survival.10,14
Multicenter clinical trials to identify best nutrition practices
and to establish laboratory monitoring guidelines across
the spectrum of care for children with IF would be opti-
mal. Collaboration among centers should be encouraged
considering the difficulty of conducting large-scale clinical
trials in this population. Collaborative initiatives such as the
Pediatric Intestinal Failure Section of ASPEN appear well
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positioned to pragmatically address the myriad variables
affecting micronutrient status in pediatric IF patients and
to issue evidence-based laboratory monitoring guidelines.
Moreover, the section can foster collaboration and take an
active role in conducting clinical research to determine best
practices for enhancing intestinal adaptation and preventing
or delaying nutrition support-related complications.
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